Developed jointly by Sanofi and Regeneron, alirocumab (Praluent) was approved 13-3 by an FDA advisory committee.
Developed jointly by Sanofi and Regeneron, alirocumab (Praluent) was approved 13-3 by an FDA advisory committee for the long-term treatment of adult patients with primary hypercholesterolemia or mixed dyslipidemia, including patients with type 2 diabetes mellitus.
However, several committee members warned about the cardiovascular (CV) effects of the drug, and discussions included whether low-density lipoprotein was indeed an appropriate surrogate for CV outcomes. The deputy director of the FDA's Division of Metabolism and Endocrinology, cautioned that if a decision was made to approve the drug, the agency would not require further assessments of cardiovascular outcomes. He therefore asked the panel to identify the population for whom the apparent cholesterol-lowering benefits of alirocumab could substitute for demonstrated clinical outcomes.
Alirocumab is being evaluated in a CV outcomes trial, with an expected completion date in 2017. However, if the drug was approved, panelists think patients would withdraw from the trial.
Read more on Medpage Today: http://bit.ly/1QoxJjc
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More